CARsgen Therapeutics Holdings Limited announced its 2023 Interim Results. Collaboration agreement for zevor-cel commercialization in mainland China with Huadong Medicine. CT041 has achieved IND clearance from the NMPA for the postoperative adjuvant therapy of Claudin18.2 positive pancreatic cancer (PC).

CT041 Phase 2 clinical trial has been initiated in the U.S. for the treatment of Claudin18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies. CARsgen and Moderna have initiated a collaboration agreement to investigate CT041 in combination with Moderna's investigational Claudin18.2 mRNA cancer vaccine. Zevorcabtagene Autoleucel is an autologous fully human CAR T-cell product candidate against B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM).

In October 2022, China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) and has granted the priority review for zevor-cel. Zevor-cel is expected to be approved by the NMPA for the treatment of R/R MM at the end of 2023 or the beginning of 2024. The enrollment in the Phase 2 clinical trial in the United States and Canada is underway.

In January 2023, CARsgen and Huadong Medicine (Hangzhou) Co. Ltd., a wholly-owned subsidiary of Huadong Medicine Co. Ltd. (Huadong Medicine) entered into a collaboration agreement for the commercialization of CARsgen's lead drug candidate, zevor-cel, in mainland China.

Since reaching the agreement, teams from CARsgen and Huadong Medicine have been working together closely to implement this collaboration and prepare for the approval and commercialization of zevor-cel in China. CT041 is an autologous humanized CAR T-cell product candidate against Claudin18.2. Based on information, CT041 is the world's first CAR T-cell candidate for the treatment of solid tumors that has entered a confirmatory Phase II clinical trial. In April 2023, CT041 has achieved IND clearance from the NMPA for the postoperative adjuvant therapy of Claudin18.2 positive pancreatic cancer (PC) (CT041-ST-05, NCT05911217).

In May 2023, a Phase 2 clinical trial of CT041 in the U.S. has been initiated for the treatment of Claudin18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies. Active CT041 trials include a Phase 1b/2 clinical trial for advanced gastric cancer (GC) and PC in the United States and Canada (CT041-ST-02, NCT04404595), a Phase Ib clinical trial for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) and PC (CT041-ST-01, NCT04581473), a confirmatory Phase II clinical trial for advanced GC/GEJ in China (CT041-ST-01, NCT04581473), and an investigator-initiated trial (NCT03874897). On August 21, 2023, CARsgen announced that CARsgen and Moderna Inc. have initiated a collaboration agreement to investigate CT041 in combination with Moderna's investigational Claudin18.2 mRNA cancer vaccine.

On top of these existing clinical programs, CARsgen will actively explore the treatment with innovative CAR T-cell products for the earlier lines of therapies. CARsgen has also been taking efforts to develop innovative technologies and product candidates that will better address the challenges with existing cell therapy products. As of June 30, 2023, the company had more than 300 patents of which 101 patents had been issued globally including China, the United States, Europe, and Japan.

This status is an increase of 9 issued patents and 24 patent applications from the end of 2022. R&D activities would continue to generate substantial intellectual property in areas of expertise.